Efficacy and safety of PD‐L1 blockade envafolimab as neoadjuvant treatment in mismatch repair‐deficient, locally advanced colorectal cancer: An open‐label, single‐arm study
This preliminary study suggests that envafolimab is a promising effective and safe neoadjuvant option for locally advanced dMMR CRC; confirmation in larger cohorts is awaited.
Authors
- Dagui Zhou
- Jianpei Liu (ORCID: https://orcid.org/0000-0003-4811-152X)
- Lijun Huang (ORCID: https://orcid.org/0000-0003-0055-9341)
- Jiafeng Fang (ORCID: https://orcid.org/0000-0002-1570-8824)
- Tufeng Chen
- Hongbo Wei (ORCID: https://orcid.org/0000-0002-1809-6544)
- Jianglong Huang (ORCID: https://orcid.org/0000-0002-0877-7418)
- Xiaofeng Yang
- Zongheng Zheng
Institutions
- Sun Yat-sen University (CN)
- Third Affiliated Hospital of Sun Yat-sen University (CN)
Publication Details
- Journal
- Cancer
- Published
- 2025-12-06
- DOI
- https://doi.org/10.1002/cncr.70203
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00